Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:11:10.432Z.
Consensus retrieved: 2026-10-06T09:54:06.909Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:11:10.432Z.
Quote observation: 2026-10-06T16:08:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
Forward PE Ratio (N/A) = Dated Quote Price ($14.91) / Consensus Forward EPS ($-1.45)
FORWARD PE RATIO
N/A
Carlsmed, Inc.
Market Cap
$405.33M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Carlsmed, Inc. (CARL) | $405.33M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $406.60M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.68M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $411.34M | N/A |
| Neurogene Inc. (NGNE)vs › | $412.52M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.87M | N/A |
| Prothena Corporation plc (PRTA)vs › | $420.92M | 73.09 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $394.39M | N/A |
| REGENXBIO Inc. (RGNX)vs › | $393.93M | N/A |
| Rezolute, Inc. (RZLT)vs › | $424.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $14.91, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.45 | $-1.50 – $-1.41 | 3 | n/m |
| 2027-12-31 | $-1.40 | $-1.46 – $-1.34 | 3 | n/m |
| 2028-12-31 | $-1.00 | $-1.28 – $-0.78 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
